Currently, there are 227.17M common shares owned by the public and among those 156.52M shares have been available to trade.
The company’s stock has a 5-day price change of 10.06% and 211.67% over the past three months. ADAP shares are trading 120.68% year to date (YTD), with the 12-month market performance up to 45.83% higher. It has a 12-month low price of $0.42 and touched a high of $1.85 over the same period. ADAP has an average intraday trading volume of 1.59 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 22.10%, 62.04%, and 107.46% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) shares accounts for 58.64% of the company’s 227.17M shares outstanding.
It has a market capitalization of $397.55M and a beta (3y monthly) value of 2.39. The earnings-per-share (ttm) stands at -$0.52. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.38% over the week and 13.01% over the month.
Analysts forecast that Adaptimmune Therapeutics Plc ADR (ADAP) will achieve an EPS of -$0.14 for the current quarter, -$0.13 for the next quarter and -$0.49 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.15 while analysts give the company a high EPS estimate of -$0.12. Comparatively, EPS for the current quarter was $0.01 a year ago. Earnings per share for the fiscal year are expected to decrease by -327.78%, and -23.38% over the next financial year. EPS should shrink at an annualized rate of 1.00% over the next five years, compared to 10.30% over the past 5-year period.
Looking at the support for the ADAP, a number of firms have released research notes about the stock. Bryan Garnier stated their Buy rating for the stock in a research note on March 24, 2023, with the firm’s price target at $3.60. Guggenheim coverage for the Adaptimmune Therapeutics Plc ADR (ADAP) stock in a research note released on January 03, 2023 offered a Buy rating with a price target of $5. Mizuho was of a view on November 09, 2022 that the stock is Buy, while Barclays gave the stock Underweight rating on May 28, 2021, issuing a price target of $4. Mizuho on their part issued Neutral rating on April 22, 2020.
